IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4773
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$47M
Frank K. Bedu-Addo
PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$PDSB PDS Biotechnology Corp | 25 | 8 | 15 | 15 | - | - | -398.4% | -108.5% | - | - | - | - | 0.0% | 190.0x | $47M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
PDS Biotechnology Corp (PDSB) receives a "Avoid" rating with a composite score of 24.8/100. It ranks #4773 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Frank K. Bedu-Addo
Chief Executive Officer
Labor Force
20
8
35
40
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for PDSB
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for PDSB.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -398.4% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 10yr history
Interest coverage -7.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags PDS Biotechnology Corp with an Avoid rating, assigning a composite score of 24.8/100 and 1 out of 5 stars. Ranked #4773 of 7,333 stocks, PDSB falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
PDS Biotechnology Corp registers a weak quality score of just 8/100, indicating significant profitability challenges. The company reports a return on equity of -398.4% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
PDSB registers a value score of just 15/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 3.76x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
PDS Biotechnology Corp's investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -108.5% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
PDS Biotechnology Corp is experiencing notably weak momentum with a score of just 15/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 1.34 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
PDSB's stability score of 40/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.34 and a debt-to-equity ratio of 190.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 56/100 for PDSB suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.34), elevated leverage (D/E: 190.00x), micro-cap liquidity risk. With a $47M market cap (micro-cap), PDS Biotechnology Corp may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
PDS Biotechnology Corp is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4773 of 7,333 overall (35th percentile). Key comparisons include ROE of -398.4% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While PDSB currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (8) would have the largest impact on the composite score.
ROE 15963% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 94900% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate PDS Biotechnology Corp (PDSB) as Avoid with a composite score of 24.8/100 at a current price of $0.66. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in stability (40th percentile) and investment (35th percentile), which together account for the majority of the composite score. Offsetting weakness in quality (8th percentile) and value (15th percentile) tempers our overall conviction. We assign a No Moat rating (14/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
PDS Biotechnology Corp holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 24.8/100 places it at rank #4773 in our full 7,333-stock universe. At $47M in market capitalization, PDS Biotechnology Corp is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (15th percentile) suggest caution regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for PDS Biotechnology Corp, which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $0.66, PDS Biotechnology Corp is trading at a premium to fundamental value. Our value factor score of 15/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 3.8x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Avoid rating (composite 24.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (190% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Weak momentum (15th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (8th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a High uncertainty rating to PDS Biotechnology Corp. Key risk factors include elevated market sensitivity (beta of 1.34), significant leverage (190% debt-to-equity), below-average price stability (40th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.34); significant leverage (190% debt-to-equity); below-average price stability (40th percentile); weak quality scores (8th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 40th percentile and quality factor at the 8th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate PDS Biotechnology Corp's capital allocation as Poor. Key concerns include low returns on equity (-398.4%), elevated leverage (190% D/E), weak asset returns (ROA -108.5%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — PDS Biotechnology Corp significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, PDS Biotechnology Corp receives a Avoid rating with a composite score of 24.8/100 (rank #4773 of 7,333). Our quantitative framework assigns a No Moat (14/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 22/100.
Our analysis does not support a constructive view on PDS Biotechnology Corp at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign PDS Biotechnology Corp a meaningful economic moat, scoring 14/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and economic value creation (2.5/20). GM N/A vs sector 43%, OM N/A vs sector 1%. ROE proxy -398.4% (sector -2.5%). These pillars form the core of PDS Biotechnology Corp's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and financial resilience (0.4/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect PDS Biotechnology Corp's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 8/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -398.4% and ROA of -108.5%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -398.4% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 190%, which may limit financial flexibility. The sector median D/E is 0%, putting PDS Biotechnology Corp at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
Above 50MA
37.18%
Net New Highs
+51081
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck CancerPRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the adoption of a protocol amendment to its Phase 3 VERSATILE-003 clinical trial. The amendment includes PFS as an interim primary endpoint to
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that results of a National Cancer Institute (“NCI”)-led study of the Company’s investigational Interleukin-12 (IL-12) tumo
PDS Biotechnology reported a Q2 2025 net loss of $0.21 per share, beating analyst expectations. The company continues advancing its immunotherapy platforms in oncology and infectious disease, with notable progress in clinical trials for HPV and colorectal cancer treatments.
Consumer Edge, the leading provider of global consumer data-driven insights, released its Home & Garden Outlook 2026, showing that consumers pulled back on large, discretionary purchases such as furniture and mattresses, while spending held up better on décor, kitchen products and essential home maintenance in 2025; a divide that continues to shape the market in 2026.
Roborock, the global leader in intelligent home robotics engineered to simplify daily life, today announced the launch of Qrevo Edge 2 Pro, its latest premium robot vacuum cleaner designed to help households stay cleaner, healthier and more comfortable — without adding extra effort to daily routines.